Livagen (20mg) is a synthetic short-peptide research material supplied as a lyophilized powder. It is intended exclusively for controlled in-vitro laboratory research involving peptide characterization and hepatic cell-model assays.
Livagen may be evaluated as an experimental test article in analytical or cell-based systems with predefined controls and measurable laboratory endpoints. Findings obtained from these systems are limited to the conditions of the assay and cannot be interpreted as evidence of safety, efficacy, or an outcome in humans or animals.
Nordsci provides independent analytical testing and lot-specific documentation for research materials. Researchers should consult the applicable Certificate of Analysis for verified identity, purity results, testing methods, and other batch-specific information.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Livagen (20mg) is a synthetic short-peptide research material supplied as a lyophilized powder. It is intended exclusively for controlled in-vitro laboratory research involving peptide characterization and hepatic cell-model assays.
Livagen may be incorporated as an experimental test article in analytical or cell-based systems with predefined controls and measurable laboratory endpoints. Observations obtained from these systems are limited to the conditions of the assay and do not establish safety, efficacy, or an outcome in humans or animals.
Livagen (20mg) – Research Specifications:
| Compound | Livagen |
| Quantity | 20mg per vial |
| Compound Type | Synthetic short-peptide research material |
| Form | Lyophilized peptide powder |
| Molecular Formula | Refer to the applicable technical or lot-specific documentation |
| Molecular Weight | Refer to the applicable technical or lot-specific documentation |
| Sequence | Refer to the applicable technical or lot-specific documentation |
| CAS Number | Refer to the applicable documentation if an identifier has been assigned |
| Purity / Identity | Consult the lot-specific Certificate of Analysis for analytical results |
| Analytical Testing | Independently tested; applicable methods and results are identified in the lot-specific COA |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture |
| Intended Use | Controlled in-vitro laboratory research and analytical evaluation only |
| Restrictions | Not for human or animal consumption, human use, veterinary use, or in-vivo procedures |
Livagen is the product designation for a synthetic short-peptide material supplied for controlled laboratory investigation. It may be evaluated through analytical methods or incorporated as a test article in in-vitro experimental systems using documented procedures, suitable controls, and predefined endpoints.
Within bioregulator research, Livagen has been associated with laboratory investigations using hepatic cell models. These experiments may examine assay-specific observations involving peptide interactions, cellular signaling markers, or other measurable analytical responses.
Experimental results obtained with Livagen remain specific to the selected model, methodology, and laboratory conditions. Such findings do not establish an effect on liver function, metabolic activity, tissue condition, or any health-related outcome in humans or animals.
Important Research Notice: Nordsci research materials include access to lot-specific analytical documentation. Certificates of Analysis are available for laboratories requiring verification of compound identity, purity results, and batch traceability.
THIS PRODUCT IS INTENDED EXCLUSIVELY FOR LABORATORY RESEARCH USE. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR HUMAN OR VETERINARY IN-VIVO USE. NOT INTENDED FOR DIAGNOSTIC, THERAPEUTIC, FOOD, DRUG, COSMETIC, OR SUPPLEMENT APPLICATIONS.
Livagen may be included as an experimental test article in controlled in-vitro assays using hepatic cell models. Researchers may document predefined signaling markers or other analytical observations under controlled laboratory conditions. These investigations do not establish an effect on liver function in humans or animals.
In-vitro research may examine assay-defined markers associated with cellular metabolic pathways. Experimental observations remain limited to the selected model and cannot be extrapolated to metabolism, energy expenditure, body composition, or other outcomes in humans or animals.
Laboratory experiments may use hepatic cell cultures to evaluate predefined cellular observations under controlled conditions. These studies do not establish tissue maintenance, regeneration, repair, protection, or organ-related outcomes.
Livagen may be evaluated in in-vitro systems designed to measure selected cellular stress-response markers. Appropriate controls and validated analytical methods are necessary to distinguish test-article observations from baseline assay variability.
Livagen (20mg) should be handled only by qualified laboratory personnel using appropriate personal protective equipment, controlled procedures, and institutional chemical-hygiene practices. The vial should remain sealed and protected from heat, light, moisture, and unnecessary temperature fluctuations.
Protocol Design Considerations: Laboratory protocols should include appropriate controls, validated analytical methods, documented experimental conditions, and predefined acceptance criteria. Researchers should record the product lot, storage history, analytical method, and relevant assay parameters for each procedure.
Livagen must not be administered to humans or animals. No dosing, administration, or consumer application guidance is provided.
This information is supplied exclusively as a laboratory research reference. All work must be conducted by qualified personnel in an appropriate research environment.
Each lot of Livagen supplied by Nordsci Peptides includes access to a Certificate of Analysis containing available batch-specific analytical information. Researchers should consult the applicable COA to confirm compound identity, purity results, testing methods, and lot traceability before incorporating the material into an experimental workflow.
Nordsci Peptides supplies Livagen (20mg) exclusively as a laboratory research material. Lot-specific analytical documentation provides qualified laboratories with information for identity review, inventory control, material tracking, and experimental documentation.
IMPORTANT: Livagen (20mg) is sold exclusively for controlled laboratory research. It is not intended for human consumption, animal consumption, therapeutic use, diagnostic use, veterinary use, food use, cosmetic use, supplement use, or any human or animal in-vivo procedure. Purchasers are responsible for complying with all applicable laws, institutional policies, and research-material requirements.
